News
Vico Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of VO659 in Huntington’s Disease and Spinocerebellar Ataxia Types 1 and 3
VO659 is the only clinical-stage candidate targeting the CAG repeat expansion that causes these diseasesVO659 was designed to preferentially reduce mutant HTT and spare wild-type HTTPhase 1/2a basket trial design and preclinical VO659 data to be presented at CHDI...
Vico Therapeutics Appoints Scott Schobel, MD as Chief Medical Officer
Dr. Schobel joins Vico from Roche where he was the clinical science leader for tominersen being developed for Huntington’s disease LEIDEN, Netherlands, October 3, 2022 – Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the...
Vico Therapeutics Appoints Micah Mackison as Chief Executive Officer
LEIDEN, Netherlands, Aug. 1, 2022 /PRNewswire/ -- Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the appointment of Micah Mackison as Chief Executive Officer. Mr. Mackison brings significant biotechnology and pharmaceutical...
Sharing RDD Colours in Leiden Science Park
BioPartner, VICO & Ntrans, joined forces this year and shared the colours to help raise awareness for Rare Disease Day, with the aim to help generate change for the 300 million people worldwide living with a rare disease including their families and carers. Our...
US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease
Leiden, The Netherlands, 29 July 2021 - VICO Therapeutics,a Leiden Bio Science Park, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan...
US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia
Leiden, The Netherlands, 29 June 2021 - VICO Therapeutics,a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan Products Development...
VICO & BioPartner Light Up on Rare Disease Day
As a friend of Rare Disease Day and to show our support in their continuous quest to raise awareness amongst the general public and decision-makers about rare diseases and their...
European Commission grants VICO Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia
Leiden, The Netherlands, 10 February 2021 - VICO Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the European Commission (EC) has granted...
Biotech VICO Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases
AON-platform with focus on therapies nearing phase I trials for forms of Spinocerebellar Ataxia and Huntington Disease Other early discovery stage RNA editing platform focuses on RETT syndrome Funding led by LSP, co-led by Kurma Partners, supported by Pontifax, Droia...
https://pubmed.ncbi.nlm.nih.gov/31821107/
Vico Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of VO659 in Huntington’s Disease and Spinocerebellar Ataxia Types 1 and 3
VO659 is the only clinical-stage candidate targeting the CAG repeat expansion that causes these diseasesVO659 was designed to preferentially reduce mutant HTT and spare wild-type HTTPhase 1/2a basket trial design and preclinical VO659 data to be presented at CHDI...
Vico Therapeutics Appoints Scott Schobel, MD as Chief Medical Officer
Dr. Schobel joins Vico from Roche where he was the clinical science leader for tominersen being developed for Huntington’s disease LEIDEN, Netherlands, October 3, 2022 – Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the...
Vico Therapeutics Appoints Micah Mackison as Chief Executive Officer
LEIDEN, Netherlands, Aug. 1, 2022 /PRNewswire/ -- Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the appointment of Micah Mackison as Chief Executive Officer. Mr. Mackison brings significant biotechnology and pharmaceutical...
Sharing RDD Colours in Leiden Science Park
BioPartner, VICO & Ntrans, joined forces this year and shared the colours to help raise awareness for Rare Disease Day, with the aim to help generate change for the 300 million people worldwide living with a rare disease including their families and carers. Our...
US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease
Leiden, The Netherlands, 29 July 2021 - VICO Therapeutics,a Leiden Bio Science Park, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan...
US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia
Leiden, The Netherlands, 29 June 2021 - VICO Therapeutics,a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan Products Development...
VICO & BioPartner Light Up on Rare Disease Day
As a friend of Rare Disease Day and to show our support in their continuous quest to raise awareness amongst the general public and decision-makers about rare diseases and their...
European Commission grants VICO Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia
Leiden, The Netherlands, 10 February 2021 - VICO Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the European Commission (EC) has granted...
Biotech VICO Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases
AON-platform with focus on therapies nearing phase I trials for forms of Spinocerebellar Ataxia and Huntington Disease Other early discovery stage RNA editing platform focuses on RETT syndrome Funding led by LSP, co-led by Kurma Partners, supported by Pontifax, Droia...
